Presentation - Product Management Service (XEVMPD) for marketing authorisation holders (M. F. Gomez, V. Baker)
Presentation - Product Management Service (XEVMPD) for marketing authorisation holders (M. F. Gomez, V. Baker)
Presentation - Product Management Service (XEVMPD) for marketing authorisation holders (M. F. Gomez, V. Baker)
Agenda of the CVMP meeting 8-10 October 2024
PSUSA/00001166/202402
PSUSA/00010867/202401
PSUSA/00000679/202401
PSUSA/00010428/202402
EMA Account Management, what's new?, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 September 2024, 10:00 (CEST) to 20 September 2024, 11:00 (CEST)
Oxbryta
Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0377/2023
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0391/2023